Immune Modulator Addition Doesn't Boost Survival in Tough Th

Despite initial promise, combining lenalidomide with cediranib didn't improve progression-free survival in differentiated thyroid cancer (DTC).

Related Keywords

, University Of Chicago Medicine Comprehensive Cancer Center , Chicago Medicine Comprehensive Cancer , Treating Recurrent , Metastatic Differentiated Thyroid Cancer , Differentiated Thyroid Cancer , Thyroid Cancer Treatment ,